Navigation Links
NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders
Date:10/29/2008

ymposium, we have an opportunity to really sharpen our focus on what it will take to effectively manage in the new world of medical pharmacy -- a world in which old technology no longer provides the tools we need, shifting sites of care are adding unexpected complexity to billing and reimbursement, and of the high-cost injectable and infusible drugs coming to market in the near term, nearly 70% will require assistance from a healthcare professional to ensure safe and proper administration. Working together I am confident we can develop creative and cost-effective solutions to meet the challenges ahead."

Note: Medical pharmacy is generally defined as prescription drugs administered in the home, outpatient clinic, or physician office and paid for under a beneficiary's medical benefit plan. Unlike prescription drugs filled at a retail pharmacy or administered in a hospital or other acute care setting and covered by a pharmacy benefit plan, this medical pharmacy segment of the overall healthcare space is often paper-based and extremely labor-intensive. And most importantly, it is plagued with significant inefficiencies that result in imprecise pricing, excessive reimbursements and overpayments, and insufficient prior authorization controls, and severely limits both government programs and commercial plans from participating fully in collecting drug manufacturers' rebates.

About NovoLogix

NovoLogix is a performance-based healthcare technology company delivering electronic claims re-pricing processes, prior authorization controls, and integrated patient care and pharmaceutical programs. Generating economic results for payers and their stakeholders and improving the management and delivery of drugs and services for healthcare consumers, Minneapolis-based NovoLogix covers millions of members for the nation's largest health plans, pharmacy benefits management companies (PBMS), and government programs. The company holds full accreditation by EHNAC. '/>"/>

SOURCE NovoLogix
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. ConvaTec Launches SUR-FIT Natura(R) Low-Pressure Adaptor
2. Capella University Launches PhD in Counselor Education and Supervision : The new degree program, one of few available online, addresses growing need for counseling faculty and supervisors
3. Caring.com Launches First Ad Network to Reach Family Caregivers
4. ECRFPlus Achieves Milestone Multimillion Dollar Enterprise Agreement With CRO and Launches e-CRF+(TM): a CTMS and EDC Web Platform With ECG Analysis and Cardiac Safety Module.
5. The Doctors Company Launches Litigation Education Retreats to Assist Physicians Involved in Medical Litigation
6. Care Improvement Plus Launches 2009 Benefits in Texas
7. St. Davids HealthCare Launches The TIA Center for Stroke Prevention at St. Davids Medical Center
8. Care Improvement Plus Launches 2009 Benefits in South Carolina
9. Care Improvement Plus Launches 2009 Benefits in Missouri
10. Care Improvement Plus Launches 2009 Benefits in Georgia
11. Care Improvement Plus Launches 2009 Benefits in Arkansas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...y could shape new treatments for secondary pneumon...swire/ -- Scientists at St. Jude Children,s Resear...atment for bacterial pneumonia following influenza...azithromycin, which kill bacteria by inhibiting th...tandard first-line treatment with the "beta-lactam...
(Date:1/8/2009)... hurtful comments, study suggests , , T...erestimate how strongly they would react to racist...e percent of study participants at York University...ment with a white person rather than a black one, ...bout the black person when he left the room. ,...
(Date:1/8/2009)...ldren,s Research Hospital have demonstrated a more...wing influenza. They found that the antibiotics cl... inhibiting their protein synthesis, are more effe...e "beta-lactam" antibiotic ampicillin, which cause...g is important because pneumonia, rather than the ...
(Date:1/8/2009)...PRNewswire-FirstCall/ -- Hanger Orthopedic Group, ...roughout the fourth quarter of 2008 it acquired Ma...ountain Orthotic-Prosthetics Center, Riessen,s Ort... Orthotics & Prosthetics, and Orthopedic Rehab...tient care centers to existing markets in Maine, L...
Breaking Medicine News(10 mins):Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:Many Turn Blind Eye to Racism 2Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2
...apeutic regimens are effective in suppressing HIV ... treatment may be complicated by development of dr...e // continued concerns over the safety of interru...clinical practice interrupt therapy for reasons re...
... reported at a seniors' home in Toronto and expert... caused the death of four residents at the home. I...here was // no cause to fear an outbreak and stres...e, "This isn't a pandemic by any means, but there ...
...arch in the areas of fetal imaging focus on modali...t women, their unborn babies and newborns with MR ...les diagnosis and treatment of many // disorders t...elayed intervention.. Fetal MRI is usually perform...
...rized by insulin resistance and/or abnormal insuli...inues to expand unabated throughout the world. The...to decreased physical activity, decreased function..., preexisting glucose and insulin abnormalities, a...
Other Medicine News:Health News:Cigarette Smoking Leads To Development Of Type 2 Diabetes In Patients With Coronary Artery Disease 2
(Date:1/8/2009)...O, Jan. 8 If you are taking prescr...re not alone. Half of the people taking,prescript...ons are,varied -- they forget, are busy with othe.... Noncompliance has been called the Achilles heel ...verett Koop commented, "Drugs don,t,work in peopl...
(Date:1/8/2009)...reated at the initial dose in an ongoing Phase Ib ...ecline after three days , , Conference Call Tod...wire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (N...irst cohort of an ongoing Phase Ib clinical trial ...oside polymerase inhibitor. ANA598 was very well-...
(Date:1/7/2009)...enn., Jan. 7 Scientists...a high likelihood of relapse in children with acut...rchers caution that further research is needed to ...or IKAROS, lead to leukemia relapse, the finding...ostic tests to assess the risk of treatment failur...
(Date:1/7/2009)... Md., Jan. 7 ImQuest Life Sciences...ND application to the Food and Drug Administration...pyrimidinedione HIV inhibitor IQP-0410. ImQuest an...first quarter of 2009. IQP-0410 is a novel small m... nonnucleoside reverse transcriptase inhibitor (NN...
Breaking Medicine Technology:Good Medicine: Smarter Smartphones for People With Chronic Disease 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 1Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 3Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 4Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 1Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 2Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 3Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 4Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 5WallSt net Announces Upcoming Interview With CEO of ReBuilder Medical Technologies 2249 1WallSt net Announces Upcoming Interview With CEO of ReBuilder Medical Technologies 2249 2LeMaitre Vascular Appoints Russell D Hays to Its Board of Directors 2247 1LeMaitre Vascular Appoints Russell D Hays to Its Board of Directors 2247 2
...oved by FDA for long-term,maintenance treatment of...nebulized formoterol fumarate provides improved lu...nhanced patient quality of,life, and positive safe...ta presented at the,International Conference of th... Perforomist™ (formoterol fumarate),Inhalati...
...The U.S. Food and Drug Administration,(FDA) is awa...(rosiglitazone), a drug approved to treat type 2 d...ls have shown that there is a,potentially signific...-related deaths in patients taking Avandia. Howeve...term clinical trials of,Avandia, including an inte...
Other Medicine Technology:Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7FDA Issues Safety Alert on Avandia 2FDA Issues Safety Alert on Avandia 3
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Medicine Products: